NeuroSense Therapeutics Ltd. (NRSN)
After hours:
| Previous close | 1.6600 |
| Open | 1.6600 |
| Bid | 1.5300 x 2200 |
| Ask | 1.6500 x 1000 |
| Day's range | 1.5500 - 1.7400 |
| 52-week range | 1.0750 - 8.1800 |
| Volume | |
| Avg. volume | 1,437,124 |
| Market cap | 19.912M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6100 |
| Earnings date | 01 Dec 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
- PR Newswire
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD). Preliminary results from the study, showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these encouraging preliminary results,
- PR Newswire
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update.
- PR Newswire
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in Italy for PARADIGM, the Company's Phase 2b clinical trial of its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling patients in Israel and recently received clearance from the U.S. Food an
